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Perioperative Probiotics or Synbiotics in Adults Undergoing
Elective Abdominal Surgery
A Systematic Review and Meta-analysis of Randomized Controlled Trials
Abeed H. Chowdhury, PhD, FRCS, Alfred Adiamah, MRCS, Anisa Kushairi, BMedSci, BM BS,
Krishna K. Varadhan, PhD, MRCS, Zeljko Krznaric, MD, PhD,y Anil D. Kulkarni, MSc, PhD,z
Keith R. Neal, DM, FRCP,§ and Dileep N. Lobo, DM, FRCS, FACS, FRCPEY
Objective: To define the impact of perioperative treatment with probiotics or
synbiotics on postoperative outcome in patients undergoing abdominal sur-
gery.
Background: Postoperative surgical infection accounts for a third of all cases
of sepsis, and is a leading cause of morbidity and mortality. Probiotics,
prebiotics, and synbiotics (preparations that combine probiotics and pre-
biotics) are nutritional adjuncts that are emerging as novel therapeutic
modalities for preventing surgical infections. However, current evidence
on their effects is conflicting.
Methods: A comprehensive search of the PubMed, Embase, and WHO
Global Index Medicus electronic databases was performed to identify ran-
domized controlled trials evaluating probiotics or synbiotics in adult patients
undergoing elective colorectal, upper gastrointestinal, transplant, or hepato-
pancreaticobiliary surgery. Bibliographies of studies were also searched. The
primary outcome measure was incidence of postoperative infectious compli-
cations. Secondary outcomes included incidence of noninfectious
complications, mortality, length of hospital stay, and any treatment-related
adverse events. Quantitative pooling of the data was undertaken using a
random effects model.
Results: A total of 34 randomized controlled trials reporting on 2723
participants were included. In the intervention arm, 1354 patients received
prebiotic or symbiotic preparations, whereas 1369 patients in the control arm
received placebo or standard care. Perioperative administration of either
probiotics or synbiotics significantly reduced the risk of infectious compli-
cations following abdominal surgery [relative risk (RR) 0.56; 95% confidence
interval (CI) 0.46–0.69; P < 0.00001, n ¼ 2723, I2 ¼ 42%]. Synbiotics
showed greater effect on postoperative infections compared with probiotics
alone (synbiotics RR: 0.46; 95% CI: 0.33–0.66; P < 0.0001, n ¼ 1399, I2 ¼
53% probiotics RR: 0.65; 95% CI: 0.53–0.80; P < 0.0001, n ¼ 1324, I2 ¼
18%). Synbiotics but not probiotics also led to a reduction in total length of
stay (synbiotics weighted mean difference: 3.89; 95% CI: 6.60 to 1.18
days; P ¼ 0.005, n ¼ 535, I2 ¼ 91% probiotics RR: 0.65; 95% CI: 2.03–
0.72; P ¼ 0.35, n ¼ 294, I2 ¼ 65%). There were no significant differences in
mortality (RR: 0.98; 95% CI: 0.54–1.80; P ¼ 0.96, n ¼ 1729, I2 ¼ 0%) or
noninfectious complications between the intervention and control groups. The
preparations were well tolerated with no significant adverse events reported.
Conclusions: Probiotics and synbiotics are safe and effective nutritional
adjuncts in reducing postoperative infective complications in elective abdom-
inal surgery. The treatment effects are greatest with synbiotics.
Keywords: elective abdominal surgery, meta-analysis, outcomes, probiotics,
synbiotics
(Ann Surg 2019;xx:xxx–xxx)
S epsis is a major problem for health care organizations around theworld and continues to be a leading cause of morbidity and
mortality, especially in postoperative patients.1,2 The frequency of
sepsis is increasing despite advances in antibiotic therapy and the
implementation of infection control policies.2–5 The limitations of
infection control strategies, as well as the increasing global concern
about antimicrobial resistance, has led to the demand for novel or
alternative strategies to reduce the risk of infection in surgical patients.
Probiotics are defined by theWorldHealthOrganization6 as live
microorganismswhich confer beneficial effects to the host when given
in sufficient quantities. They survive transit through the gastrointesti-
nal tract with the majority of their activity being in the colon.7
Prebiotics are food ingredients, which escape digestion in the upper
gastrointestinal tract to stimulate the growth or activity of selective
bacterial genera in the colon.8 When prebiotics and probiotics are
combined in a single preparation they are known as synbiotics.9 These
nutritional adjuncts have emerged as potential treatments that could
help reduce the incidence of postoperative infection.
Probiotics have been shown to be useful in the treatment of
gastrointestinal infections; they are effective along with oral rehy-
dration therapy in treating acute infectious diarrhea in children,10–13
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traveller’s diarrhea,14 and antibiotic-associated diarrhea in both
children15–17 and adults.18–21 Mechanisms of action for probiotics
include competitive exclusion of potentially pathogenic bacteria and
direct antimicrobial effects.22 Probiotics alter the pH of intestinal
mucosa, produce bacteriocins which inhibit pathogenic epithelial
adherence and production of virulence factor, and prevent bacterial
translocation via tight junctions.22,23 Furthermore, probiotic bacteria
have also been shown to promote anti-inflammatory cytokine pro-
duction.22,24 The proliferation of probiotic bacteria can be enhanced
by the co-administration of prebiotics; and certain bacterial genera
are stimulated selectively by these compounds which supply
nutrients for their growth.25
A number of randomized controlled trials (RCTs) have exam-
ined the value of prebiotics and probiotics in reducing postoperative
complications with mixed results, most likely due to variations in
methodological quality and endpoints. Serious adverse effects of
probiotics are uncommon in those who are well, but it is theorized
that these may occur in patients with impaired immunity. In patients
with severe pancreatitis, administration of probiotics was associated
with an increased frequency of bowel ischemia.26,27 This potential
for adverse effects of probiotics warrants systematic review before
their use in the perioperative setting can be recommended. This
systematic review and meta-analysis of RCTs evaluated the effect of
perioperative probiotics or synbiotics on postoperative infections in
adult patients undergoing elective abdominal surgery.
METHODS
The methodology for this meta-analysis was approved by the
Cochrane Collaboration and the protocol was published in the
Cochrane Library: Cochrane Database of Systematic Reviews
2011, Issue 7. Art. No.: CD009246. DOI: 10.1002/14651858.
CD009246. This strategy was amended since publication of the
protocol to extend the search dates to 2018.
Search Strategy
RCTs were identified from PubMed (1966–2018), Embase
(1980–2018), and World Health Organization (WHO) Global Index
Medicus. Search terms were used and connected by Boolean oper-
ators AND/OR and included Population: Adults Intervention: Probi-
otic, Probiotic, Synbiotics, Individual species/preparations. Disease
condition: Abdominal Surgery, Operation, Laparotomy, Colorectal
resection, Pancreatic Surgery, Infection, Sepsis, Collection, Abscess.
References from relevant articles were scanned and primary authors
consulted for additional information as necessary. Bibliographies of
RCTs, meta-analyses, and systematic reviews were hand-searched
for studies that were not captured by the initial search. Unpublished
or ongoing studies were identified by checking clinical trials regis-
ters. The complete strategy for identifying RCTs is described in the
Supplementary Document, http://links.lww.com/SLA/B774.
Inclusion and Exclusion Criteria
Only RCTs evaluating perioperative probiotics or synbiotics
in patients aged 18 years and older having elective abdominal surgery
(including laparoscopic surgery) were included. Studies which
included patients younger than 18 years of age or pregnant women
were excluded.
The perioperative administration of probiotics or synbiotics
given by any route, duration, combinationor preparationwas accepted.
Control groupswere defined as those that didnot receive anyprobiotics
or synbiotics and received either placebo or standard care.
Outcome Measures
The primary outcome was incidence of postoperative infec-
tious complications as defined by the trial authors in each of the
studies included, with a pre-planned subgroup analysis based on the
type of preparations (probiotics and synbiotics). Secondary outcome
measures included incidence of non-infectious postoperative com-
plications, primary length of hospital stay (LOS), 30-day mortality,
and any other reported adverse events. A further analysis based on the
source of funding as reported in the individual studies, was under-
taken to assess the role of this on outcome of studies.
Selection of Studies
The studies identified from the electronic searches were
evaluated independently by 2 reviewers (A.H.C. and A.A.) using
a study eligibility form based on the inclusion criteria. Titles and
abstracts were initially screened for relevance. The full texts of
potential studies were then retrieved, assessed independently and any
discordance adjudicated by a third reviewer (D.N.L.).
Data Extraction and Management
Two reviewers (A.H.C. and .A.A.) extracted data indepen-
dently from the full text publications of the RCTs that met the
inclusion criteria using a standardized data extraction form and data
were validated by a third reviewer (D.N.L.).
Data Analysis
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement methodology28 was adhered to. Studies
were appraised critically and the risk of bias of all included studies
assessed according to the guidelines of The Cochrane Collabora-
tion.29 Relative risk (RR) was reported along with 95% confidence
intervals (CIs) to estimate treatment effects or discrete numerical
variables. Weighted mean difference (WMD) was used for reporting
continuous outcomes. Pooled data were analyzed using the random-
effects model with the inverse variance or Mantel-Haenszel method
as appropriate. As studies may have used different lengths of
treatment, studies were subjected to metaregression to determine
the most effective duration of treatment. Heterogeneity was quanti-
fied using the I2 statistic, with the values of 25%, 50%, and 75%
signifying the limits of low, moderate, and high statistical heteroge-
neity, respectively.30 A funnel plot was used to explore publication
bias for the studies included. All statistical analyses were performed
using RevMan 5.3 software.31
RESULTS
The initial literature search identified 196 potential studies for
inclusion in this analysis. Following application of exclusion criteria,
34 studies were deemed appropriate for full analysis (Fig. 1).
A large proportion of studies were excluded because they did
not fulfill criteria for human RCTs, for example, they were not
randomized, were performed as retrospective analyses, or were
animal studies. Additional studies were excluded on the basis that
they did not use probiotics, prebiotics, or synbiotics or were not
undertaken in patients undergoing elective abdominal surgery.
Eleven studies were excluded as they did not report infectious
complications. An attempt to contact the authors (n ¼ 8) was made
for publications that qualified for analysis but did not contain the
required information in the manuscript, but the responses were
limited.
Studies Included
Of the 34 studies32–65 included in the final analysis, 16 used
probiotics33,34,37,38,42–48,58,60,62,63,65 as the sole intervention with the
remaining 18 studies using synbiotic preparations32,35,36,39–41,49–
57,59,61,64 in comparison with placebos or standard care. All the
studies identified were published after the year 2000. In total,
2723 participants were included in this analysis, of whom 1354
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were randomized to receive either probiotic or synbiotic prepara-
tions, whereas 1369 received placebo or standard care.
Participants and Interventions
The mean (standard deviation) age of study participants
receiving probiotics or synbiotics was 62.8 (11.4) and 62.4 (10.8)
years for those receiving placebo or standard care. A variety of
abdominal operations were included: elective colorectal, upper
gastrointestinal, transplant, or hepatopancreaticobiliary surgery. Of
the studies using probiotics alone, only 3 used a preparation con-
taining a single probiotic species; Lactobacillus plantarum 299v46,47
or Bifidobacteria58 with the remainder using a mixture of probiotics.
Similarly, of the studies using synbiotics, only 3 used preparations
containing a single probiotic species.52,54,61 One study compared the
use of either synbiotics or prebiotics with heat-deactivated probiotics
to standard care.39 There were insufficient data to include prebiotics
alone as a separate subgroup in this meta-analysis. An overview of
the studies included32–65 and their design is summarized in Table 1.
Tolerance and Side Effects of Interventions
There were no serious complications or deaths directly related
to the intake of either probiotics or synbiotics. On the whole, intake
was well tolerated, and rates of abdominal distension, cramps, and
diarrhea were not significantly elevated compared to the placebo or
standard care group. Adverse effects are summarized in Table 2.
Postoperative Infectious Complications
Data on postoperative infectious complications were reported
in all 34 studies.32–65 Quantitative pooling of data showed a signifi-
cant reduction in the incidence of postoperative infectious compli-
cations in the intervention group (Fig. 2). The risk of developing a
postoperative infectious complication was almost halved (RR 0.56;
95% CI 0.46–0.69; P < 0.00001, I2 ¼ 42%).
In subgroup analysis, there was significant reduction in the
incidence of postoperative infectious complications when both inter-
vention types were considered separately. However, the reduction
in infectious complications was greater in participants receiving
FIGURE 1. PRISMA diagram detailing the study selection and exclusion process.
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synbiotics (RR: 0.46; 95% CI: 0.33–0.66; P < 0.0001, I2 ¼ 53%)
than in those receiving probiotics alone (RR: 0.65; 95% CI: 0.53–
0.80; P < 0.0001, I2 ¼ 18%).
Duration of Treatment
Studies were subjected to a weighted linear multiple regres-
sion to determine the influence of treatment duration on incidence of
postoperative infectious complications. The results of this weighted
analysis demonstrated that although there was a trend for a reduction
in postoperative infectious complications with increasing treatment
duration, this relationship, was not statistically significant (r2 ¼
0.0047, P ¼ 0.4554).
Length of Hospital Stay
A total of 12 studies40,43,44,51,52,54–57,59,61,63 reported on the
outcome of length of primary hospital stay. Analysis of pooled data
revealed a statistically significant difference between treatment
groups (WMD: 2.59; 95% CI: 4.31 to 0.87, P ¼ 0.003, I2 ¼
88%) (Fig. 3A). However, in subgroup analysis, the decrease in
length of stay was only significant in the synbiotics group (WMD:
TABLE 2. Summary of Gastrointestinal Adverse Effects Associated With Probiotic and Synbiotic Ingestion in the Randomized
Controlled Trials Included
Study Probiotic Synbiotic Placebo or Standard Care P
Anderson et al, 200432 – Diarrhea: 4/72
Unpalatable: 1/72
Not stated –
Consoli et al, 201633 Not stated – NS
Diepenhorst et al, 201134 Ileus: 1 – Ileus: 1 –
Eguchi et al, 201135 – Poor tolerance: 0/25 Poor tolerance: 0/25 –
Flesch et al, 201736 – Not stated Not stated –
Gianotti et al, 201037 Not stated – Not stated –
Grat et al, 201738 Diarrhea: 4/24 – Diarrhea: 3/26 0.99
Nausea: 1/24 Nausea: 2/26
Constipation: 1/24 Constipation: 1/26
Horvat et al, 201039 – Not stated Not stated –
Kanazawa et al, 200540 – Not stated Not stated –
Komatsu et al, 201641 – Not stated Not stated –
Kotzampassi et al, 201542 Not stated – Not stated –
Liu et al, 201144 Diarrhea: 11/50 – Diarrhea: 11/50 <0.05
Cramps: 9/50 Cramps: 9/50
Distension: 13/50 Distension: 13/50
Liu et al, 201345 Diarrhea: 11/75 – Diarrhea: 22/75 0.03
Liu et al, 201543 Diarrhea: 16/66 – Diarrhea: 31/68 0.012
Cramps: 15/66 Cramps: 33/68 0.017
Distension: 22/66 Distension: 35/68 0.038
Mangell et al, 201246 Not stated – Not stated –
McNaught et al, 200247 Unpalatable: 9/69 – Not stated –
Nausea: 9/69
Ileus: 12/69
Nomura et al, 200748 Delayed gastric
emptying: 3/30
Delayed gastric
emptying: 7/34
0.1
Okazaki et al, 201349 – Not stated Not stated –
Polakowski et al, 201950 – Flatulence: 4/36 Flatulence: 3/37 0.34
Rammohan et al, 201551 – Not stated Not stated –
Rayes et al, 200252 Distension, cramps
or diarrhea: 6/31
– Distension, cramps or
diarrhea: 11/32
–
Rayes et al, 200254 Distension: 3/30 – Distension: 6/30 –
Cramps: 4/30 Cramps: 5/30
Rayes et al, 200556 – Diarrhea: 2/33 Diarrhea: 3/33 –
Cramps: 5/33 Cramps: 6/33
Rayes et al, 200755 – Diarrhea: 2/40 Diarrhea: 2/40 –
Cramps: 3/40 Cramps: 6/40
Rayes et al, 201253 – Diarrhea: 3/9 Diarrhea: 3/10 –
Cramps: 3/9 Cramps: 3/10
Russolillo et al, 201457 – Diarrhea: 3/20 Not stated –
Nausea: 4/20
Sadahiro et al, 201458 Not stated – Not stated –
Sommacal et al, 201559 – Not stated Not stated –
Tan et al, 201660 Not stated – Not stated
Usami et al, 201161 – Not stated Not stated –
Woodard et al, 200962 Not stated – Not stated –
Yang et al, 201663 Diarrhea: 8/30 – Diarrhea: 16/30 0.035
Distension: 9/30 Distension: 13/30 0.284
Yokoyama et al, 201664 – Not stated Not stated –
Zhang et al65 Not stated Not stated Not stated –
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3.89; 95% CI: 6.60 to 1.18; P ¼ 0.005, I2 ¼ 91%) and not
significant in the small probiotics only group (WMD: 0.65, CI:
2.03–0.72, P ¼ 0.35, I2 ¼ 65%).
Mortality
A total of 23 studies32,33,35,37,39–41,43,44,46–50,53,55–57,59–62,64
reported data on mortality. Twelve studies33,37,39–41,43,44,49,53,56,61,62
recorded no deaths in either treatment arm. There was no significant
difference in mortality between patients receiving probiotics or
synbiotics compared with those who received placebo or standard
care (RR: 0.98; 95%CI: 0.54–1.80; P¼ 0.96, I2¼ 0%) (Fig. 3B) this
was also confirmed on subgroups analysis.
Noninfectious Complications
Some studies provided a count of the number of participants
with noninfectious complications; others reported the different types
of complications but not the number of patients with these compli-
cations. In addition, what counted as noninfectious complications
differed between individual studies, as such formal pooling of this
outcome could not be undertaken. However, where number of
patients with noninfectious complications were reported there was
no significant difference between the treated and control arms in the
individual studies.34,35,38,39,41,42,46,48–50,52,53,55–57,59–61,63–65
Impact of Source of Funding
We undertook a separate analysis to assess the impact corporate
funding had on the primary outcome. Studies were stratified into
‘‘industry sponsored,’’ ‘‘undeclared,’’ and ‘‘not industry sponsored’’—
the RR favored probiotics/synbiotics in all cases [‘‘industry sponsored’’
RR 0.65 (95%CI 0.53–0.81, P< 0.0001, I2¼ 49%); ‘‘undeclared’’ RR
0.47 (95% CI 0.31–0.72, P ¼ 0.0006, I2 ¼ 52%) and ‘‘not industry
sponsored’’ RR 0.25 (95% CI 0.09–0.69, P ¼ 0.007, I2 ¼ 17%).
FIGURE 2. Forest plot of pooled data from randomized controlled trials demonstrating the reduction in risk of infectious
complications.
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FIGURE 3. Forest plot of (A) pooled weighted mean difference from randomized controlled trials demonstrating the effect on risk
ratio for length of hospital stay and (B) mortality with probiotic and synbiotic perioperative treatment.
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Publication Bias
It is recognized that studies are more likely to be published if
positive outcomes are demonstrated. Consequently, published studies
may not be truly representative of all valid studies undertaken. The
assessment of publication bias based on the primary outcome of
infectious complications showed minor asymmetry in favor of
positive studies with fewer studies which cross the margin of no
effect (Fig. 4).
Risk of Bias Analysis
The risk of bias of the studies included is summarized in
Figure 5.
DISCUSSION
What This Study Found
The analysis of pooled data from RCTs demonstrates that the
perioperative administration of probiotics and synbiotics signifi-
cantly reduces the risk of infectious complications following abdom-
inal surgery, with the magnitude of this risk reduction approaching
50%. The reduction in risk of infections was greater with synbiotic
preparations than with probiotics alone, confirming that the benefi-
cial effects of probiotics can be enhanced by the addition of prebiotic
substrates. In addition, there was a reduction in LOS in the synbiotic
group but not the probiotics group. There was no impact on nonin-
fectious complications or mortality.
The studies included in this meta-analysis employed different
treatment durations; the majority of the larger studies which provided
most of weighting had treatment durations lasting more than 10 days.
The reduction in infection risk remained whether treatment was
given for less than 10 days or for 10 days or more. Separate weigthed
metaregression of treatment duration against RR of infection did not
reveal a significant relationship. This might be accounted for by 2
possible explanations, possibly that a minimum treatment duration is
sufficient to observe an effect above which no additional effect is
seen, or that the analysis lacks studies with a sufficient range of
treatment durations thereby diminishing power. It is, therefore,
difficult to infer either minimum or optimum duration of treatment
from this analysis.
What is Available in the Literature
The reduction in infectious complications demonstrated in this
meta-analysis are consistent with the results of other systematic
reviews.66–69 In addition, Kinross et al67 also found a similarly
pronounced benefit of synbiotics over probiotics. A reduction in
postoperative infectious complications was also found in studies
carried out in patients undergoing nonabdominal surgery.70
Importantly, both probiotics and synbiotics were tolerated
well and were associated with few gastrointestinal adverse effects,
even in participants who had undergone major gastrointestinal
reconstructions or liver transplantation, where a significant degree
of immunosuppression can occur. The serious complications of
probiotic usage observed in nonsurgical patients such as bowel
ischemia26 and Lactobacillus-related sepsis71 were not evident in
the setting of elective abdominal surgery. It is noteworthy that the
increased risk of bowel ischemia as detected in the PROPATRIA
study26 has not been validated by a second study, thereby making the
true clinical relevance of this association uncertain. Furthermore, a
meta-analysis of 2972 critically ill patients admitted to the intensive
care unit found no differences in rates of mortality between those
who received probiotics and thosewho did not.72 Hence, the potential
detrimental impact of probiotics in the acutely unwell patient has not
been substantiated by this meta-analysis.72 The present meta-analy-
sis also did not demonstrate any significant side effects of probiotics
in the setting of elective abdominal surgery.
The studies varied in the types of patients and complexity of
surgery carried out, ranging from elective colorectal resections for
benign disease to complex hepatopancreaticobiliary resections and
reconstructions for malignant disease. It would be expected that
patients undergoing more complex surgery would be subject to a
greater risk of complications and mortality and longer hospital stay.
This was borne out in the data which showed that mortality was
generally low in studies on colorectal surgery compared with hep-
atopancreaticobiliary surgery. On the whole, mortality rates were
low, with the highest recorded for the study by Anderson et al32 with
an overall mortality rate of 10.2%. This might be considered slightly
high in the setting of elective abdominal surgery. Overall, there were,
however, no significant differences in mortality demonstrated
between patients who received probiotics or synbiotics (21 of 849
FIGURE 4. Funnel plot of included ran-
domized controlled trials demonstrating
the treatment effect relative to study
size. SE indicates standard error.
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patients, 2.5%) compared with those receiving placebo or standard
care (23 of 880 patients, 2.6%). The prior reviews also identified no
differences in noninfectious complications or mortality.66–69
Perioperative administration of probiotics and synbiotics was
seen to decrease length of stay significantly by 2 days in 12 studies
that reported length of stay. There was, however, a high degree of
statistical heterogeneity in the pooled synthesis. Length of stay is
influenced by many confounding factors and not necessarily directly
related to the incidence of infection. Length of stay data are also
subject to bias if blinding of patients, healthcare staff, and study data
analysts to treatment groups is not effective.
Although this meta-analysis does not provide any evidence for
mechanism of action, it does indicate a role for the addition of
prebiotic compounds to enhance the action of probiotics. Patients
undergoing major abdominal surgery would be expected to experi-
ence a period of postoperative gut dysfunction which may have
several important implications when administering probiotic or syn-
biotic preparations. For instance, delivery of probiotic bacteria to
their proposed site of action may be impaired in the presence of
vomiting or paralytic ileus. Any delay in the return to normal gut
function may also disrupt local bacterial ecology and prevent the
establishment of probiotic niches due to the impaired delivery of
probiotic substrates during periods of inadequate enteral nutrition.
Although this meta-analysis has shown a clear reduction in the
risk of infectious complications with probiotics and synbiotics, there
was no significant effect on noninfectious complications, consistent
with the proposed theory of the gut as an origin of sepsis and in
agreement with the earlier reviews.66,67 Noninfectious complications
are also likely to be influenced by confounding factors such as patient
cohort, complexity of surgery, and access to critical care facilities.
The analysis based on the source of funding demonstrated that the
impact of probiotics and synbiotics on the primary outcome was
preserved regardless of whether the studies were industry funded,
undeclared, or unfunded.
It is difficult, from this analysis, to determine which probiotic
or synbiotic strains were most effective in reducing infectious
complications as the variability in species and genera used in the
studies was wide. The majority of the studies used Lactobacilli either
alone or in combinations with prebiotics. Twenty-one stud-
ies32,35,37,38,40–44,48–51,57–60,63–65 used Bifidobacteria species,
whereas galacto-oligosaccharides, known to selectively enhance
the growth of Bifidobacteria,73,74 were used in 6 of the stud-
ies.35,40,49,57,61,64 At present it is not certain whether some strains
of probiotic bacteria are more effective at reducing infection risk than
others. This, however, clearly remains an area for further study. In
addition, 2 recent studies have suggested that the same probiotic
supplement may behave differently in different individuals.75,76
Probiotics may not colonize the gut of all patients, suggesting that
the bacteria may pass through the gastrointestinal tract of some
people with no effect.76 The same group of investigators also showed
that compared with spontaneous postantibiotic recovery, probiotics
induced a delayed and incomplete return of the native microbiota and
that potential postantibiotic benefits of probiotics may be offset by a
compromised gut mucosal recovery.75 It has been proposed that in
the not too distant future machine learning algorithms could be used
to predict which particular strains of probiotics would be most
beneficial on an individual patient basis.75–77 Although this is
promising, it remains only a hypothesis at present.
Strengths and Limitations
This systematic review and meta-analysis comprehensively
assessed clinically relevant outcomes in patients undergoing elective
gastrointestinal surgery. It included searches of the major online
databases as well as theWHOGlobal IndexMedicus, allowing studies
FIGURE 5. Risk of bias analysis for the studies included.
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from low- andmiddle-income countries countries to also be identified.
The focus on elective gastrointestinal surgery, helped reduce thewithin
study and between study variability and heterogeneity.
There are however, a number of limitations to this analysis
which warrant discussion. Firstly, there has been no standardization
of preparation of probiotic, duration of treatment, or route of
administration making comparison of the trials challenging. In
addition, some studies have used synbiotics or multispecies prepa-
rations. Furthermore, control groups in some studies comprised only
standard care, whereas other studies employed a placebo. This lack
of consistency is likely to introduce significant heterogeneity and
whilst we attempted to account for this by employing a random
effects meta-analysis, this must be borne in mind when drawing any
conclusions. Other sources of heterogeneity include the use of
preoperative bowel preparation, pre- and postoperative antibiotic
usage, and surgical technique, which were all, in general, reported
poorly in all the studies. Large high-quality multicenter studies
would be needed to reduce the influence of these factors.
Different probiotics and synbiotic preparations were used in the
RCTs included, with some employing a singular strain and others a
cocktail or combinations of strains (Table 1).As such subgroup analysis
basedon strainof probiotics usedcould not be achieved in any clinically
meaningfully way due to the wide spread of strains used in the
individual studies. More work is required in exact strain identification
and characterization of strain-specific clinical effects. Although peri-
operative administration of probiotics and synbiotics used in the studies
included in this meta-analysis demonstrated a reduction in infectious
complications, all probiotic bacterial strains cannot be interpreted as
equivalent.As such the clinicallybeneficial effects of a select numberof
bacterial strains cannot be simply extrapolated to other strain(s) of
probiotics not yet subjected to a rigorous RCT. It must, therefore, be
stressed that the findings of thismeta-analysis are only applicable to the
strains studied in the individual RCTs.
This would ensure future reviews could pursue analysis of
benefit based on different probiotic strain preparations to potential
identify which species of probiotics or synbiotics harbor the most
clinical benefit.
CONCLUSIONS
Probiotics and synbiotics are safe in the setting of elective
abdominal surgery and associated with few adverse effects. Both
probiotics and synbiotics reduce the risk of postoperative infection
but the effect is greater for synbiotics than for probiotics. Further
large multicenter studies with standardization of probiotic and syn-
biotic preparations, participants, type of surgery, and postoperative
care are required before the effectiveness of particular preparations
and optimum duration of treatment can be established.
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